Pulmonary Allergy Drugs Advisory Committee

September 6, 2002

Holiday Inn Gaithersburg

7:30 Introductions Dr. Mark Dykewicz

COI Ms. Kimberly L. Topper

Welcome Dr. Robert Meyer

Dr. Badrul Chowdhury

8:00 Boehringer Ingelheim Presentation's

Introduction and Overview Dr. Burkhard Blank

Bronchodilator Efficacy in COPD Dr. Bernd Disse

Quantification of Dyspnea Dr. Paul Jones

Dyspnea and Related Measures Dr. Theodore Witek

Clinical Safety Evaluation Dr. Steven Kesten

Clinical Perspective Dr. James Donohue

Conclusions Dr. Burkhard Blank

9:30 Break

9:45 Food and Drug Administration Presentation's

Transition Dyspnea Index (TDI) Dr. Lisa Kammerman

PK/PD, Safety & Efficacy Dr. Eugene Sullivan

11:15 General Discussion and Clarification

12:00 Lunch

1:00 Open Public Hearing

2:00 Discussion of Questions

3:30 Adjourn